Welcome to our dedicated page for Esperion Therape SEC filings (Ticker: ESPR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Esperion Therapeutics filings document the regulatory record of a commercial-stage biopharmaceutical company focused on LDL-C lowering, cardiovascular-risk therapies, and related cardiometabolic programs. Its Form 8-K reports cover operating and financial results, clinical or regulatory disclosures, material agreements, capital-structure matters, and material-event updates tied to its commercial portfolio and development activities.
Esperion's SEC record also includes proxy disclosures on shareholder voting, board governance, executive compensation, equity awards, and pay-versus-performance information. Recent filings describe common stock registered on Nasdaq under ESPR, term-loan and credit-agreement amendments, acquisition-related financing, commercial leadership appointments, and other governance and compensation arrangements.
THOMPSON JOHN CRAIG reported acquisition or exercise transactions in this Form 4 filing.
Esperion Therapeutics director John Craig Thompson received an equity award of 79,873 shares of common stock as compensation. The award was granted at no cash cost per share and represents his entire reported direct holding after the transaction. These shares vest in full on the earlier of May 28, 2027 or the company’s next annual meeting of stockholders following May 28, 2026.
Esperion Therapeutics director Jay Shepard reported an equity award of 79,873 shares of Common Stock. The shares were granted at no purchase price as a stock award and increase his direct holdings to 164,472 shares after the transaction.
The award vests in full on the earlier of May 28, 2027, or the company’s next annual meeting of stockholders following May 28, 2026, aligning vesting with future board service. This filing reflects compensation-related share acquisition rather than an open-market purchase or sale.
Hoffman Robert E. reported acquisition or exercise transactions in this Form 4 filing.
Esperion Therapeutics director Robert E. Hoffman received an equity grant of 79,873 shares of Common Stock, reported at a price of $0.00 per share as a compensation award. Following this grant, he directly holds 85,153 shares of Esperion common stock.
The award vests in full on the earlier of May 28, 2027 or Esperion’s next annual meeting of stockholders following May 28, 2026, linking vesting to either time-based service or the company’s stockholder meeting schedule.
Fischer Seth H. Z. reported acquisition or exercise transactions in this Form 4 filing.
Esperion Therapeutics director Seth H. Z. Fischer received an equity award of 79,873 shares of common stock as compensation. The grant carried a price of $0.00 per share and increased his directly held stake to 141,023 shares.
The award vests in full on the earlier of May 28, 2027, or the company’s next annual meeting of stockholders following May 28, 2026, meaning the shares are subject to a service-based vesting condition rather than being immediately unrestricted.
CARROLL J MARTIN reported acquisition or exercise transactions in this Form 4 filing.
Esperion Therapeutics, Inc. director J. Martin Carroll received an equity grant of 79,873 shares of Common Stock as compensation. The shares were awarded at no cash cost per share and increase his direct holdings to 177,523 shares. The award vests in full on the earlier of May 28, 2027 or the company’s next annual meeting of stockholders following May 28, 2026.
Esperion Therapeutics, Inc. reported results from its 2026 annual stockholder meeting. Stockholders approved an amendment to the 2022 Stock Option and Incentive Plan to increase the shares of common stock authorized for issuance under the plan by 7,000,000 shares.
As of March 31, 2026, there were 257,404,876 shares of common stock outstanding and entitled to vote, and 177,208,856 shares were present or represented by proxy, establishing a quorum. Stockholders elected Class I directors J. Martin Carroll and Sheldon L. Koenig, approved the advisory vote on executive compensation, and ratified Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
Esperion Therapeutics is asking shareholders to approve a proposed merger under an Agreement and Plan of Merger dated May 1, 2026 in which Essence Parent Inc. (an affiliate of ArchiMed) will acquire the company.
Under the merger, each share of Company common stock (other than excluded or appraisal shares) would be converted into $3.16 in cash plus one Contingent Value Right (CVR) that may pay up to $40,000,000 (bempedoic acid milestone) and $60,000,000 (enbumyst milestone) if specified U.S. sales thresholds are met. The Board unanimously recommends shareholders vote FOR the merger, an advisory vote on transaction-related executive compensation, and an adjournment proposal if needed. The merger is subject to customary conditions, including shareholder approval, expiration/termination of the HSR waiting period and German merger clearance, and other closing conditions. Financing sources disclosed include an equity commitment of up to $706,100,000 and a debt commitment up to $550,000,000. Appraisal rights under Delaware law are available to eligible dissenting stockholders.
Esperion Therapeutics reported Q1 2026 revenue of $80.1 million, up from $65.0 million a year earlier, and a narrower net loss of $25.2 million versus $40.5 million. Product sales were $43.4 million and collaboration revenue $36.7 million, driven mainly by partners in Europe and Japan.
Cash and cash equivalents were $156.2 million, alongside substantial obligations including a $291.2 million royalty sale liability and $250 million of term and convertible debt. The company agreed to acquire Corstasis for $75 million plus up to $180 million in milestones, adding Enbumyst to its cardiovascular portfolio.
Separately, Esperion entered into a definitive merger agreement under which Essence Parent Inc. will acquire the company. Holders of common stock will receive $3.16 in cash per share plus one contingent value right tied to up to $100 million of potential milestone-based cash payments, subject to stockholder approval and customary conditions.
Esperion Therapeutics agreed to be acquired by Essence Parent Inc., an affiliate of ARCHIMED. Under the merger agreement, shareholders will receive $3.16 in cash per share plus one contingent value right (CVR) per share, which can pay up to $100 million in cash in total if specified milestones are met.
The deal values Esperion’s equity at up to approximately $1.1 billion on a fully diluted basis and the cash price reflects a 58% premium to the April 30, 2026 closing share price. The transaction, unanimously approved by Esperion’s board, is expected to close in the third quarter of 2026, subject to shareholder and regulatory approvals and other customary conditions. Termination fees are set at $68,309,078 for Parent and $34,154,539 for Esperion in specified circumstances.
Esperion Therapeutics ownership disclosure: institutional investor Wasatch Advisors reports beneficial ownership of 15,768,897 shares of Common Stock, representing 6.1% of the class. The filing shows sole voting power of 12,377,523 shares and sole dispositive power of 15,768,897. The filing is signed by Mike Yeates, CEO, dated 04/22/2026.